Free Trial
→ I'm giving you a space stock today. Free. (From Behind the Markets) (Ad)tc pixel Free BCLI Stock Alerts

Brainstorm Cell Therapeutics (BCLI) Competitors

Brainstorm Cell Therapeutics logo
$0.84 +0.00 (+0.41%)
As of 03:13 PM Eastern
Compare

BCLI vs. CNTB, YARW, INMB, IMA, and EXOZ

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? Brainstorm Cell Therapeutics's main competitors and comparable companies include Connect Biopharma (CNTB), Yarrow Bioscience (YARW), INmune Bio (INMB), ImageneBio (IMA), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Brainstorm Cell Therapeutics compare to Connect Biopharma?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Brainstorm Cell TherapeuticsN/A N/A -519.50%
Connect Biopharma N/A -165.41%-121.58%

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A
Connect Biopharma$60K964.28-$55.48M-$1.19N/A

In the previous week, Connect Biopharma had 8 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 9 mentions for Connect Biopharma and 1 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.67 beat Connect Biopharma's score of 0.17 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Brainstorm Cell Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Connect Biopharma
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Brainstorm Cell Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market.

Connect Biopharma has a consensus target price of $5.88, suggesting a potential upside of 539.42%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Connect Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

Summary

Connect Biopharma beats Brainstorm Cell Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Yarrow Bioscience-4,726.21% -84.40% -77.68%
Brainstorm Cell Therapeutics N/A N/A -519.50%

Yarrow Bioscience currently has a consensus target price of $58.00, indicating a potential upside of 211.83%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Yarrow Bioscience is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yarrow Bioscience
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Yarrow Bioscience and Yarrow Bioscience both had 1 articles in the media. Yarrow Bioscience's average media sentiment score of 0.91 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company Overall Sentiment
Yarrow Bioscience Positive
Brainstorm Cell Therapeutics Positive

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yarrow Bioscience$570K87.13-$26.48M-$14.64N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

Yarrow Bioscience has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Yarrow Bioscience beats Brainstorm Cell Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

INmune Bio has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INmune Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Brainstorm Cell Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
INmune BioN/A -82.87% -62.23%
Brainstorm Cell Therapeutics N/A N/A -519.50%

In the previous week, INmune Bio and INmune Bio both had 1 articles in the media. INmune Bio's average media sentiment score of 0.91 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that INmune Bio is being referred to more favorably in the media.

Company Overall Sentiment
INmune Bio Positive
Brainstorm Cell Therapeutics Positive

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune Bio$50K932.40-$45.93M-$0.67N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

Summary

INmune Bio beats Brainstorm Cell Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImageneBio$800K60.16-$45.35M-$4.58N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

ImageneBio has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

In the previous week, ImageneBio had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for ImageneBio and 1 mentions for Brainstorm Cell Therapeutics. ImageneBio's average media sentiment score of 1.38 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that ImageneBio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImageneBio
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Brainstorm Cell Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Brainstorm Cell Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity.

Company Net Margins Return on Equity Return on Assets
ImageneBioN/A -38.99% -34.84%
Brainstorm Cell Therapeutics N/A N/A -519.50%

ImageneBio presently has a consensus price target of $29.00, suggesting a potential upside of 583.96%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImageneBio is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImageneBio
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ImageneBio beats Brainstorm Cell Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat eXoZymes' return on equity.

Company Net Margins Return on Equity Return on Assets
eXoZymesN/A -292.15% -158.66%
Brainstorm Cell Therapeutics N/A N/A -519.50%

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 58.0% of eXoZymes shares are held by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

eXoZymes has higher revenue and earnings than Brainstorm Cell Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eXoZymes$70K609.81-$9.16M-$1.19N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eXoZymes
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, eXoZymes had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Brainstorm Cell Therapeutics. eXoZymes' average media sentiment score of 1.18 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that eXoZymes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
eXoZymes
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Brainstorm Cell Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

eXoZymes has a beta of 3.19, meaning that its stock price is 219% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Summary

eXoZymes beats Brainstorm Cell Therapeutics on 9 of the 11 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCLI vs. The Competition

Export
MetricBrainstorm Cell TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11.91M$3.90B$7.28B$12.92B
Dividend YieldN/A3.65%2.51%22.89%
P/E Ratio-0.2512.49275.2825.28
Price / SalesN/A1,151.22562.3878.55
Price / CashN/A118.5077.1653.04
Price / Book-0.6116.5510.525.92
Net Income-$11.62M-$22.69M$3.50B$381.04M
7 Day Performance-7.23%-6.66%-4.32%-4.41%
1 Month Performance-21.43%-14.41%-8.66%-7.30%
1 Year Performance19.29%5.91%1.94%-5.04%

Brainstorm Cell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCLI
Brainstorm Cell Therapeutics
N/A$0.84
+0.4%		N/A+26.0%$11.91MN/AN/A40
CNTB
Connect Biopharma
3.0316 of 5 stars		$0.91
+0.8%		$6.14
+578.5%		-49.5%$56.54M$60KN/A64
YARW
Yarrow Bioscience
2.3819 of 5 stars		$18.73
-7.7%		$58.00
+209.7%		N/A$54.20M$570KN/A30
INMB
INmune Bio
0.61 of 5 stars		$1.87
-3.6%		N/A-8.2%$53.84M$50KN/A21
IMA
ImageneBio
3.3572 of 5 stars		$4.60
-2.2%		$29.00
+531.1%		-44.9%$53.35M$800KN/A18

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel